StageOther Investors | Alive
About Neucel Specialty Cellulose
Neucel Specialty Cellulose produces a variety of specialty cellulose products. It offers products such as Cellulose Viscose, Cellulose Acetate, Cellulose Nitrate, Cellulose Ethers, and more. It was founded in 2006 and is based in Richmond, Canada.
Missing: Neucel Specialty Cellulose's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Neucel Specialty Cellulose's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Neucel Specialty Cellulose News
Feb 4, 2011
Wellspring Exits Neucel Specialty Cellulose February 4, 2011 Fulida Group Holdings has acquired Neucel Specialty Cellulose from a consortium of investors led by Wellspring Capital Management. Financial terms of the deal were not released. Fulida is one of the world’s largest producers of rayon. Neucel produces hemlock based chemical cellulose that is used in manufacturing processes including rayon filament for garments, pharmaceuticals, consumer products, film, food thickeners and LCD screens. PRESS RELEASE Fulida Group Holdings Ltd (“Fulida”) has purchased Neucel Specialty Cellulose from a consortium of investors led by Wellspring Capital Management. Fulida, together with Zhejiang Fulida Ltd, which had established a minority equity position along with a strategic supply agreement with Neucel in 2010, is now assuming full ownership of the company. Financial terms of the transaction were not disclosed. “We are very pleased to become fully integrated into the Fulida organization given their leadership in the rayon market and their strong support of our Port Alice Mill. The new ownership enables Neucel to explore new growth opportunities while continuing our aggressive cost and capacity initiatives. Wellspring has been a visionary and dedicated owner of our business and we are very pleased to have helped make this a successful investment for them,” said Bob Taylor, President and CEO of Neucel who will continue to lead the business. “Viscose rayon fibre competition in China has become intense. With the purchase of Neucel, Fulida gains a stable supply of dissolving pulp along with cost advantages and quality assurance which extends the value chain of our business. I strongly believe that this purchase will ensure a stable, sustainable and rapid development for Neucel, and thus help it to further achieve its unique enterprise value,” said Jianer Qi, Chairman of Fulida Group Holdings. Fulida is one of the leading producers of rayon in the world with several awards to its credit within the Chinese textile industry. Joshua Cascade, a Partner of Wellspring, commented, “We are very proud of what Neucel has accomplished in recent years. The mill’s success is a result not only of our investment, but of the vision and commitment of our management team, the hard work of the mill’s employees, and the support of local officials and governments. Today, the Neucel mill is a symbol of Port Alice’s stability and future, and we believe it will continue to thrive as part of Fulida. We are honored to have partnered with Bob Taylor and his team and the town of Port Alice, and wish them every success in the future.” About Fulida Group Holdings Ltd Fulida Group Holdings Ltd. was founded in 1988. It is situated by Hangzhou Bay, adjacent to the City of China Light & Textile Industry. Fulida Group Holdings is a highly integrated textile manufacturer with “Fulida” as a widely recognized brand name. It controls nine major companies including textile, printing and dyeing, thermal electricity, viscose fiber, chemical, foreign trade and real estate etc. About Neucel Specialty Cellulose Ltd. Neucel produces hemlock based high-purity chemical cellulose that is used in a wide range of manufacturing processes including rayon filament for garments, pharmaceuticals, consumer products, film, food thickeners, LCD screens and other products. For more information on Neucel, visit the company website at www.neucel.com. About Wellspring Capital Management Wellspring Capital Management, founded in 1995, is a leading middle market private equity firm that manages more than $3 billion of private equity capital. The firm’s objective is to bring partnership, experience and value creation to each investment. By teaming up with strong management, Wellspring is able to unlock underlying value and pursue new growth opportunities through strategic initiatives, operating improvements and add-on acquisitions. The firm functions as a strategic rather than tactical partner, providing management teams with top-line support, M&A experience and financial expertise, and access to resources. © 2015 Buyouts Insider / Argosy Group LLC
Neucel Specialty Cellulose Frequently Asked Questions (FAQ)
When was Neucel Specialty Cellulose founded?
Neucel Specialty Cellulose was founded in 2006.
Where is Neucel Specialty Cellulose's headquarters?
Neucel Specialty Cellulose's headquarters is located at 11331 Coppersmith Way, Richmond.
What is Neucel Specialty Cellulose's latest funding round?
Neucel Specialty Cellulose's latest funding round is Other Investors.
Who are the investors of Neucel Specialty Cellulose?
Investors of Neucel Specialty Cellulose include Lexington Partners, GSC Group, Wellspring Capital Management and Charlestown Investments.
Who are Neucel Specialty Cellulose's competitors?
Competitors of Neucel Specialty Cellulose include Cognate BioServices, MetaBiologics, HumanZyme, Fusion Antibodies, Roka Bioscience and 10 more.
Compare Neucel Specialty Cellulose to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Biomm offers a recombinant human protein production platform.
EMTech, a spin-off of BiOva, LLC, is researching, developing, and manufacturing technologies for the metabolic enhancement of the enzymes and bacteria used in the fermentation industry. The company's current products and ongoing research projects show applications that enhance productivity in the ethanol, pharmaceutical, beer, wine, and dairy industries.
Adimab is engaged in the discovery, maturation and production of therapeutic human antibodies. Per the company, Adimab integrates all aspects of antibody discovery and sophisticated screening methods, and therefore can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. The company states that their proprietary library design and presentation technology allows Adimab to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.
Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
Matrix Sensors aims to democratize air quality sensors for a cleaner, healthier, and safer world.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.